110 related articles for article (PubMed ID: 10594470)
21. Retrospective population pharmacokinetics of levocetirizine in atopic children receiving cetirizine: the ETAC study.
Hussein Z; Pitsiu M; Majid O; Aarons L; de Longueville M; Stockis A;
Br J Clin Pharmacol; 2005 Jan; 59(1):28-37. PubMed ID: 15606437
[TBL] [Abstract][Full Text] [Related]
22. Orogastric and intravenous indomethacin administration to very premature neonates with patent ductus arteriosus: population pharmacokinetics, absolute bioavailability, and treatment outcome.
Al Za'abi M; Donovan T; Tudehope D; Woodgate P; Collie LA; Charles B
Ther Drug Monit; 2007 Dec; 29(6):807-14. PubMed ID: 18043480
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Hatlebakk JG; Berstad A
Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai soldiers.
Edstein MD; Kocisko DA; Brewer TG; Walsh DS; Eamsila C; Charles BG
Br J Clin Pharmacol; 2001 Dec; 52(6):663-70. PubMed ID: 11736877
[TBL] [Abstract][Full Text] [Related]
25. Influence of cisapride on food-stimulated gastro-oesophageal reflux: a radiological study.
Gelineck J; Aksglade K; Funch-Jensen P; Thommesen P
Rontgenblatter; 1990 Aug; 43(8):352-4. PubMed ID: 2204995
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic profile of cisapride 20 mg after once- and twice-daily dosing.
Zhou H; Herron J; Clyde C; Lee P; Mechlinski W; Pesco-Koplowitz L
Clin Ther; 1998; 20(2):292-8. PubMed ID: 9589820
[TBL] [Abstract][Full Text] [Related]
27. Cisapride for gastro-oesophageal reflux and peptic oesophagitis.
Cucchiara S; Staiano A; Capozzi C; Di Lorenzo C; Boccieri A; Auricchio S
Arch Dis Child; 1987 May; 62(5):454-7. PubMed ID: 3300570
[TBL] [Abstract][Full Text] [Related]
28. Population pharmacokinetics of intramuscular gentamicin administered to young infants with suspected severe sepsis in Kenya.
Thomson AH; Kokwaro GO; Muchohi SN; English M; Mohammed S; Edwards G
Br J Clin Pharmacol; 2003 Jul; 56(1):25-31. PubMed ID: 12848772
[TBL] [Abstract][Full Text] [Related]
29. Unreliable rectal absorption of cisapride in horses.
Steel CM; Bolton JR; Preechagoon Y; Charles BG
Equine Vet J; 1999 Jan; 31(1):82-4. PubMed ID: 9952334
[No Abstract] [Full Text] [Related]
30. [QTc interval in newborns with gastroesophageal reflux treated with cisapride and ranitidine].
Lista G; Maestri L; Meroni M; Massari D; Colli A; Porcelli F; Menchini M; Introvini P; Compagnoni G
Acta Biomed Ateneo Parmense; 2000; 71 Suppl 1():633-6. PubMed ID: 11424819
[TBL] [Abstract][Full Text] [Related]
31. Drug interactions with cisapride: clinical implications.
Michalets EL; Williams CR
Clin Pharmacokinet; 2000 Jul; 39(1):49-75. PubMed ID: 10926350
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetic characteristics of cisapride in elderly patients.
Yamamoto T; Takano K; Sanaka M; Kuyama Y; Yamanaka M; Koike Y; Mineshita S
Int J Clin Pharmacol Ther; 1998 Aug; 36(8):432-4. PubMed ID: 9726696
[TBL] [Abstract][Full Text] [Related]
33. [Lengthening of the QT-interval in a newborn treated with cisapride].
Heeringa M; Pulles-Heintzberger CF; van Puijenbroek EP; Verduijn MM
Ned Tijdschr Geneeskd; 1999 Oct; 143(42):2108-11. PubMed ID: 10560562
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetics of Oral Topotecan in Infants and Very Young Children with Brain Tumors Demonstrates a Role of ABCG2 rs4148157 on the Absorption Rate Constant.
Roberts JK; Birg AV; Lin T; Daryani VM; Panetta JC; Broniscer A; Robinson GW; Gajjar AJ; Stewart CF
Drug Metab Dispos; 2016 Jul; 44(7):1116-22. PubMed ID: 27052877
[TBL] [Abstract][Full Text] [Related]
35. Effects of cisapride on ventricular depolarization-repolarization and arrhythmia markers in infants.
Zamora SA; Belli DC; Ferrazzini G; Friedli B
Biol Neonate; 2001 Jul; 80(1):30-4. PubMed ID: 11474146
[TBL] [Abstract][Full Text] [Related]
36. Comparative bioavailability of two immediate release tablets of cisapride in healthy volunteers.
Maya MT; Domingos CR; Guerreiro MT; Filipe AP; Morais JA
Eur J Drug Metab Pharmacokinet; 1998; 23(3):377-81. PubMed ID: 9842980
[TBL] [Abstract][Full Text] [Related]
37. Effect of cisapride on secondary peristalsis in patients with gastroesophageal reflux disease.
Holloway RH; Penagini R; Schoeman MN; Dent J
Am J Gastroenterol; 1999 Mar; 94(3):799-803. PubMed ID: 10086669
[TBL] [Abstract][Full Text] [Related]
38. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
Desta Z; Soukhova N; Mahal SK; Flockhart DA
Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
[TBL] [Abstract][Full Text] [Related]
39. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
Staatz CE; Tett SE
Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
[TBL] [Abstract][Full Text] [Related]
40. A double-blind placebo-controlled study on prophylactic use of cisapride on feed intolerance and gastric emptying in preterm neonates.
Reddy PS; Deorari AK; Bal CS; Paul VK; Singh M
Indian Pediatr; 2000 Aug; 37(8):837-44. PubMed ID: 10951632
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
